top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau Medical to Participate in September Investor Conferences
JERUSALEM, August 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 24, 2023
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha
- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year...
Aug 21, 2023
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
JERUSALEM, August 02, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 2, 2023
Alpha Tau Medical to Participate in June Investor Conferences
JERUSALEM, May 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 25, 2023
Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treated the first...
May 24, 2023
First treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
-First patient treated in the feasibility and safety study of intratumoral diffusing alpha-emitters radiation therapy (Alpha DaRT) for...
May 18, 2023
Alpha Tau Announces Publication: US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
- The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or...
May 12, 2023
Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day
JERUSALEM, May 03, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 4, 2023
Alpha Tau & JGH Announce Alpha Dart treatment of First Patient in Pancreatic Cancer Clinical Trial
-First patient treated in the feasibility and safety study of intratumoral diffusing alpha radiation emitters for the treatment of...
Apr 3, 2023
Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit
JERUSALEM, March 30, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Mar 30, 2023
bottom of page